ABBV-GMAB-3013
Showing 1 - 25 of 107
B-Cell Non-Hodgkin Lymphoma Trial in China (Epcoritamab, Cyclophosphamide, Rituximab)
Recruiting
- B-Cell Non-Hodgkin Lymphoma
- Epcoritamab
- +6 more
-
Beijing, Beijing, China
- +20 more
May 31, 2022
DLBCL, Follicular Lymphoma Trial in United States (Epcoritamab)
Recruiting
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
-
Fountain Valley, California
- +38 more
Jul 27, 2022
DLBCL Trial in Worldwide (Epcoritamab, Cyclophosphamide, Rituximab)
Recruiting
- Diffuse Large B-Cell Lymphoma
- Epcoritamab
- +5 more
-
Birmingham, Alabama
- +376 more
Jan 30, 2023
ABBV-951 Subcutaneous Infusion to Assess Change in Disease
Not yet recruiting
- Parkinson's Disease (PD)
- (no location specified)
Oct 25, 2023
Subcutaneous Infusion of ABBV-951 to Assess Change in Disease
Not yet recruiting
- Parkinson's Disease (PD)
- (no location specified)
Jun 15, 2023
Advanced Solid Tumors Cancer Trial in Worldwide (ABBV-151, Budigalimab)
Recruiting
- Advanced Solid Tumors Cancer
-
New Haven, Connecticut
- +29 more
Dec 5, 2022
ABBV-154 Trial in Grayslake, Las Vegas (ABBV-154 Dose Formulation A, ABBV-154 Dose Formulation B)
Active, not recruiting
- ABBV-154
- ABBV-154 Dose Formulation A
- ABBV-154 Dose Formulation B
-
Grayslake, Illinois
- +1 more
Dec 19, 2022
Upper Limb Spasticity Trial (ABBV-950, BOTOX, Placebo for ABBV-950)
Not yet recruiting
- Upper Limb Spasticity
- ABBV-950
- +2 more
- (no location specified)
Jul 14, 2023
Unresectable Metastatic Colorectal Cancer Trial (ABBV-400, Bevacizumab, Folinic Acid)
Not yet recruiting
- Unresectable Metastatic Colorectal Cancer
- ABBV-400
- +4 more
- (no location specified)
Oct 25, 2023
DLBCL, Chronic Lymphocytic Leukemia, B Cell Malignancies Trial in Australia, United States (ABBV-525)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- +3 more
-
Louisville, Kentucky
- +6 more
Nov 14, 2022
Relapsed/Refractory Multiple Myeloma Trial in Japan (ABBV-383)
Recruiting
- Relapsed/Refractory Multiple Myeloma
-
Kashiwa-shi, Chiba, Japan
- +5 more
Jan 25, 2023
ALS, Amyotrophic Lateral Sclerosis Trial in Canada, United States (ABBV-CLS-7262, Placebo)
Active, not recruiting
- ALS
- Amyotrophic Lateral Sclerosis
- ABBV-CLS-7262
- Placebo
-
Irvine, California
- +13 more
Jan 20, 2023